QDOT MICRO BI-DIRECTIONAL NAVIGATION CATHETER; QDOT MICRO UNI-DIRECTIONAL NAVIGATION CATHETER
Biosense Webster, Inc. · Decision date Sep 15, 2026
What did the FDA decide?
Biosense Webster, Inc. received an OK30 decision dated 2026-09-15 for PMA supplement P210027/S019, a 30-Day Notice filed under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The supplement identifier links it to PMA P210027 for the QDOT MICRO bi-directional and uni-directional navigation catheters, product code OAE, described in the database as a percutaneous cardiac ablation catheter for treatment of atrial fibrillation. The notice's stated purpose is adding another supplier for critical components; the record does not name the components, the supplier, or the affected manufacturing site, and it gives no safety or performance data.
The decision does not approve the QDOT MICRO system as a new device; it covers a supplier change within the existing PMA. The reported purpose is a manufacturer's description of the change, not independent evidence of safety or clinical effectiveness, and the record states no new indication or clinical findings.
FDA approval order statement
an additional supplier for critical components
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 15, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P210027/S019
- Regulatory pathway
- PMA supplement
- Applicant
- Biosense Webster, Inc.
- Product code
- OAE
- Decision code
- OK30
- Decision date
- Sep 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation.
- Applicant
- Biosense Webster, Inc.
- Product code
- OAE
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P210027. Subsequent supplements may change the device or its indications.
FDA decision timeline
P210027 · Original PMA
QDOT MICRO System
P210027/S019 received
Application receipt date recorded by FDA.
P210027/S018 · Related supplement
QDOT MICRO System
P210027/S019 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P210027. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210027
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
QDOT MICRO SystemP210027 | Biosense Webster, Inc. | PMA approval | Nov 23, 2022 | FDA |
QDOT MICRO SystemP210027/S018 | Biosense Webster, Inc. | PMA supplement | Sep 10, 2026 | FDA |
Explore the linked device profile
Other records with product code OAE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
STOP Persistent AFP100010/S154 | Medtronic Cryocath, LP | PMA supplement | Sep 25, 2026 | FDA |
TactiFlex Ablation Catheter, Sensor EnabledP220013/S034 | ABBOTT MEDICAL | PMA supplement | Sep 22, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Sep 4, 2026 | FDA | |
| ABBOTT MEDICAL | PMA approval | May 18, 2023 | FDA | |
| Medtronic Cryocath, LP | PMA approval | Dec 17, 2010 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biosense Webster, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 31 Technology Dr., Suite 200, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P210027/S019
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


